Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel
Isoforms Recommended:	N-type calcium channel

Results for "

N-type calcium channel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (26) Drug Derivative (1) Drug Isomer (1) Reference Standards (1) Sodium Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (4) Inflammation/Immunology (3) Neurological Disease (24)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Calcium Channel CaSR Calmodulin Calpain CRAC Channel PNPLA3

Cat. No.	상품명	Target	연구분야	Chemical Structure

HY-P0062B

Ziconotide acetate 2 Publications Verification SNX-111 acetate	Calcium Channel	Cardiovascular Disease Inflammation/Immunology Cancer
Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .

HY-P0062

Ziconotide SNX-111	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .

HY-120751

TROX-1	Calcium Channel	Neurological Disease
TROX-1 is a selective, orally active and brain-penetrant **N-type calcium channel (Cav2.2) inhibitor with an IC₅₀** value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .

HY-103309

ML218 2 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active *T-type* Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3*, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type* calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-14462

NP118809 39-1B4	Calcium Channel	Cardiovascular Disease
NP118809 is a potent **N-type calcium channel blocker, with an IC₅₀** of 0.11 μM; also less potently inhibits L-type calcium channel with an IC₅₀ of 12.2 μM.

HY-103318

PD173212 3 Publications Verification	Calcium Channel	Neurological Disease
PD173212 is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC₅₀ of 36 nM in IMR-32 assays.

HY-100310

N-type calcium channel blocker-1	Calcium Channel	Neurological Disease
N-type calcium channel blocker-1 is an orally active compound which shows high affinity to functionally block **N-type calcium channels with an IC₅₀** of 0.7 μM in the IMR32 assay.

HY-119373

Cav 2.2 blocker 1 1 Publications Verification	Calcium Channel	Neurological Disease
Cav 2.2 blocker 1 (compound 9) is a N-type calcium channel (Cav 2.2) blocker for the treatment of pain, with an IC₅₀ of 1 nM .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-147638

MONIRO-1	Calcium Channel	Neurological Disease
MONIRO-1 is a T-type and N-type **calcium channel blocker with IC₅₀ values of 34, 3.3, 1.7 and 7.2 µM against hCa_v2.2, hCa_v3.1, hCa_v3.2 and hCa_v3.3*, respectively. MONIRO-1 has low activity against L-type* calcium channels. MONIRO-1 can be used for the study of pain and epilepsy .

HY-U00236

PD0176078	Calcium Channel	Cardiovascular Disease
PD0176078 is a newly found N-type **Calcium channel** blocker.

HY-105365

PD 175069	Calcium Channel	Neurological Disease
PD 175069 is a potent and selective **N-type calcium channel antagonist with an IC₅₀** of 0.32 μM. PD 175069 is efficacious in an audiogenic seizure model using DBA/2 mice. PD 175069 can be used for research on neurological conditions such as neuropathic pain and stroke .

HY-126336

HM12	Calcium Channel	Cardiovascular Disease Neurological Disease
HM12 is a covalent inhibitor of L-/T-type calcium channels. HM12 can strongly inhibit the Cav1.2 (L-type) and Cav3.2 (T-type) calcium channels, and has selectivity for the N-type channels. HM12 produces an irreversible inhibition that persisted after washout. HM12 can be used to study diseases such as hypertension, pain, epilepsy, etc .

HY-P0062A

Ziconotide TFA SNX-111 TFA	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .

HY-120484

A-1048400	Calcium Channel	Neurological Disease
A-1048400 is an orally active and selective **calcium channel inhibitor with an IC₅₀** value of 1.4 μM for N-type channels, 1.2 μM for T-type channel. A-1048400 inhibits neurotransmitter release and reduces membrane hyperexcitability, exerting potent analgesic activity. A-1048400 is promising for research of neuropathic pain (e.g., pain induced by spinal nerve ligation and chronic constriction injury) .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P5179

Huwentoxin I HWTX-I	Calcium Channel Sodium Channel	Neurological Disease
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type **calcium channels*. Huwentoxin I inhibits sodium channels* in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC₅₀ values of 66.1 and 4.80 nM, respectively .

HY-118974

PD-151307	Calcium Channel	Neurological Disease Cancer
PD-151307 is an N-type **calcium channel antagonist with significant inhibitory effects in IMR-32 human neuroblastoma cells, exhibiting an IC₅₀** of 0.32 µM. PD-151307 can be used in research related to cancer therapy, anticonvulsants, and neuropathic pain .

HY-P2699

ω-Grammotoxin SIA GrTx; ω-GsTx SIA	Calcium Channel	Neurological Disease
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated **Calcium channels** inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .

HY-103309A

ML218 hydrochloride	Calcium Channel	Neurological Disease
ML218 hydrochloride is a potent, selective and orally active *T-type* Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3*, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type* calcium channels, K_ATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .

HY-W269511

NW-1689	Drug Derivative	Neurological Disease
NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM can be used for the study of Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium channels and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research .

HY-182351

ONO-2921	Calcium Channel	Neurological Disease
ONO-2921 is an orally active and selective **N-type calcium channel** blocker. ONO-2921 functionally blocks N-type calcium channels. ONO-2921 reduces paw withdrawal responses during persistent nociception and hyperalgesia to heat in neuropathic pain models. ONO-2921 can be used for research on neuropathic pain and nociceptive pain .

HY-103309S

ML218-d9	Calcium Channel	Neurological Disease
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-147639

Cav 2.2/3.2 blocker 1	Calcium Channel	Neurological Disease
Cav 2.2/3.2 blocker 1 (Compound 9e) is a neuronal calcium channel blocker with IC₅₀ values of 78 μM and 80 μM against Ca_v2.2 and Ca_v3.2, respectively. Cav 2.2/3.2 blocker 1 can penetrate the CNS .

HY-120751A

(S)-TROX-1	Drug Isomer Calcium Channel	Neurological Disease
(S)-TROX-1 is the S-enantiomer of TROX-1 (HY-120751). TROX-1 is a selective, orally active and brain-penetrant **N-type calcium channel (Cav2.2) inhibitor with an IC₅₀** value of 0.11 μM. TROX-1 exerts state-dependent and use-dependent inhibition, preferentially targets open/inactivated channels, blocks depolarization-associated calcium influx, and fully blocks calcium influx in rat dorsal root ganglion neurons. TROX-1 reverses inflammatory-induced hyperalgesia, nerve injury-induced allodynia. TROX-1 can be used for the research of pain .

HY-103309R

ML218 (Standard)	Reference Standards Calcium Channel	Neurological Disease
ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

Cat. No.	상품명	Target	Research Area

HY-P0062B

Ziconotide acetate 2 Publications Verification SNX-111 acetate	Calcium Channel	Cardiovascular Disease Inflammation/Immunology Cancer
Ziconotide acetate (SNX-111 acetate), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide acetate reduces synaptic transmission, and can be used for chronic pain research .

HY-P0062

Ziconotide SNX-111	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide (SNX-111), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide reduces synaptic transmission, and can be used for chronic pain research .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-P0062A

Ziconotide TFA SNX-111 TFA	Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Ziconotide TFA (SNX-111 TFA), a peptide, is a potent and selective block of **N-type calcium channels** antagonist. Ziconotide TFA reduces synaptic transmission, and can be used for chronic pain research .

HY-P1078

Huwentoxin XVI	Calcium Channel	Neurological Disease
Huwentoxin XVI, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P1078A

Huwentoxin XVI TFA	Calcium Channel	Neurological Disease
Huwentoxin XVI TFA, an analgesic, is a highly reversible and selective mammalian **N-type calcium channel (IC₅₀** of ~60 nM) antagonist from Chinese tarantula Ornithoctonus huwena. Huwentoxin XVI TFA has no effect on voltagegated T-type calcium channels, potassium channels or sodium channels .

HY-P5179

Huwentoxin I HWTX-I	Calcium Channel Sodium Channel	Neurological Disease
Huwentoxin I (HWTX-I) is a peptide toxin that inhibits voltage-gated sodium channels and N-type **calcium channels*. Huwentoxin I inhibits sodium channels* in rat hippocampus and cockroach dorsal unpaired median (DUM) neurons with IC₅₀ values of 66.1 and 4.80 nM, respectively .

HY-P2699

ω-Grammotoxin SIA GrTx; ω-GsTx SIA	Calcium Channel	Neurological Disease
ω-Grammotoxin SIA (GrTx) is P/Q and N-type voltage-gated **Calcium channels** inhibitor. ω-Grammotoxin SIA is also a protein toxin that can be obtained from spider venom. ω-Grammotoxin SIA has the potential to study neurological diseases as well as cardiovascular diseases .

Cat. No.	상품명	Chemical Structure

HY-103309S

ML218-d9
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

온라인 문의

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
호칭			Country or Region *
고객명 *			회사명 *
Department *
메일주소 *			상품명 *
Cat. No.			Requested quantity *
전화번호 *
비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: